APOBEC3B mRNA Expression in Breast Cancer Correlates with Genomic Mutational Signatures
Despite advances in screening and treatment, breast cancer remains a leading cause of cancer-related mortality. APOBEC enzymes, particularly APOBEC3B (A3B), are upregulated in many cancers, contributing to a characteristic C-to-T mutational signature found in 30-50% of breast cancers. However, the relationship between A3B mutational signatures and A3B expression across subtypes, and the resulting…
Breast cancer remains a leading cause of cancer-related deaths, despite advancements in detection and treatment methods. APOBEC enzymes, particularly APOBEC3B (A3B), have been found to be upregulated in numerous cancers, leading to a distinctive C-to-T mutational signature observed in 30-50% of breast cancer cases. However, the connection between A3B mutational signatures, A3B expression levels, and the subsequent biological implications across various breast cancer subtypes has not been extensively explored.
Researchers utilized datasets from the TCGA and ICGC cancer genomics projects to investigate the relationship between A3B mRNA expression and APOBEC enrichment scores. Pathway enrichment analyses, including KEGG, GO, and Reactome pathways, were conducted to identify biological processes linked with high A3B expression, with a focus on stratifying by breast cancer intrinsic subtypes, such as HR+/HER2-, HR+/HER2+, HR-/HER2+, and triple-negative breast cancer (TNBC).
The findings indicate that over 64% of tumors showing enriched A3B mutational genomic signatures displayed above-median A3B mRNA expression levels (p < .05).
Written by urgent.news from bioRxiv's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
